Women's Right To Choose Avastin Debated During House PDUFA Hearing
Executive Summary
Discussion of the status of Avastin's indication for metastatic breast cancer at a July 7 House hearing can be seen as a surrogate for several debates that could unfold during the user fee reauthorization process – including FDA approval standards, conflict-of-interest screening for advisory committees and pricing.
You may also be interested in...
Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on
FDA Commissioner Margaret Hamburg’s willingness to explore changes in conflict-of-interest policies for advisory committee members, coupled with a push for reforms by industry and lawmakers, suggests a relaxation of current screening requirements could become an easy add-on to the Prescription Drug User Fee Act reauthorizing legislation in 2012.
Conflict-Of-Interest Policy Relaxation For FDA Cmtes. Could Be Easy PDUFA Add-on
FDA Commissioner Margaret Hamburg’s willingness to explore changes in conflict-of-interest policies for advisory committee members, coupled with a push for reforms by industry and lawmakers, suggests a relaxation of current screening requirements could become an easy add-on to the Prescription Drug User Fee Act reauthorizing legislation in 2012.
Genentech Losing Its Legs? Avastin Study Proposal Undercut By Feasibility, Scientific Concerns
Genentech’s proposal to run a new confirmatory trial of Avastin (bevacizumab) while the first-line metastatic breast cancer claim remains on label was undermined by practical considerations raised at the June 28-29 hearing on CDER's proposal to withdraw the indication.